ArticleClinical parkinsonism & related disorders2026
Validation of the Norwegian version of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale.
Article in Clinical parkinsonism & related disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The Movement Disorder Society-revised version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) is the gold standard assessment for evaluating Parkinson's disease (PD) symptoms and severity, but a validated Norwegian version is not yet available. We translated the original English MDS-UPDRS into Norwegian and tested the clinimetrics of the translated version following the MDS-established protocol for non-English language translations. Methods: Two independent teams translated the English version of the MDS-UPDRS into Norwegian. After review of the back-translated English version, cognitive pretesting was performed in twelve PD patients at one study site. This was followed by large-scale testing completed by 351 native Norwegian-speaking PD patients at six centers across Norway. We applied confirmatory and exploratory factor analyses to determine the validity of the Norwegian version. Additional analyses were performed to test the reliability of the translated scale. Results: Confirmatory factor analysis demonstrated that the factor structure of the Norwegian version was consistent with that of the English version, as indicated by comparative fit indexes of ≥0.90 for all four MDS-UPDRS parts. Exploratory factor analysis showed the same number of factors in each MDS-UPDRS part, compared to the English version, with some differences in item loadings. Cronbach's α values were >0.70 for all four MDS-UPDRS parts. Conclusion: The Norwegian language MDS-UPDRS has good construct validity and internal consistency, meeting the requirements to be designated as the Official Norwegian Version of the MDS-UPDRS. We recommend using this validated version in both research and clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.